In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Neurology BioPharmaceutical

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market

  • Analysis

Executive Summary

Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.

You may also be interested in...



VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety

Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions. 

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Table

View full table

Topics

Related Companies

Tags:
Leadership Neurology BioPharmaceutical
Latest Headlines

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

China VBP, Localization And Other Strategies - How Far And Which Way?

See All
UsernamePublicRestriction

Register

IV123574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By